Agenus Inc. (AGEN)
AGEN Price and Sentiment
AGEN Latest news
Why Agenus Was Rising High on Tuesday
2021-11-09 16:21The biotech delivers better-than-expected Q3 results.
Agenus Inc. (AGEN) CEO Garo Armen on Q3 2021 Results - Earnings Call Transcript
2021-11-09 14:13Agenus Inc. (AGEN) CEO Garo Armen on Q3 2021 Results - Earnings Call Transcript
Agenus (AGEN) Beats Q3 Earnings and Revenue Estimates
2021-11-09 10:43Agenus (AGEN) delivered earnings and revenue surprises of 50.00% and 38.15%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Agenus Corporate Update and Third Quarter 2021 Financial Report
2021-11-09 08:00LEXINGTON, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided a corporate update and reported financial results for the third quarter of 2021.
Agenus to Participate in Fireside Chat at the B. Riley Fall 2021 Growth Biotech Best Ideas Series
2021-11-09 08:00LEXINGTON, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven O'Day, Chief Medical Officer, and Dr. Dhan Chand, Scientific Director, Head of Drug Discovery at Agenus, will participate in a fireside chat hosted by B. Riley on Monday, November 15, 2021 at 12:00 PM EST. Dr. O'Day and Dr. Chand will discuss the AGEN1181 program (Fc-enhanced CTLA-4), following presentation of clinical data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting on Friday, November 12th, 2021.
Agenus to Participate in Webcast Hosted by William Blair to Discuss AGEN1181 Clinical Data from SITC 2021 Meeting
2021-11-04 08:30LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven O'Day, Chief Medical Officer at Agenus and Dr. Manuel Hidalgo, Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and New York-Presbyterian/Weill Cornell Medical Center, will participate in a webcast hosted by Dr. Matt Phipps, biotechnology analyst at William Blair on Friday, November 12, 2021 at 12:00 p.m. ET.
Agenus (AGEN) Reports Next Week: Wall Street Expects Earnings Growth
2021-11-02 16:05Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Penny Stocks To Watch For November With Potential Biotech Catalysts
2021-10-31 10:30Biotech penny stocks to watch with upcoming events this week. The post 5 Penny Stocks To Watch For November With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Down 33.3% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround
2021-10-26 11:50The heavy selling pressure might have exhausted for Agenus (AGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Agenus to Provide Corporate Update and Third Quarter 2021 Financial Report
2021-10-25 08:30Conference Call on Tuesday, November 9, 2021, at 8:30 a.m. ET Conference Call on Tuesday, November 9, 2021, at 8:30 a.m. ET